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Polymorphisms in ovine PrP at amino acid residues 141 and 154 are associated with susceptibility to ovine prion disease:
Leu141Arg154 with classical scrapie and Phe141Arg154 and Leu141His154 with atypical scrapie. Classical scrapie is naturally trans-
missible between sheep, whereas this may not be the case with atypical scrapie. Critical amino acid residues will determine the
range or stability of structural changes within the ovine prion protein or its functional interaction with potential cofactors, during
conversion of PrPC to PrPSc in these different forms of scrapie disease. Here we computationally identified that regions of ovine
PrP, including those near amino acid residues 141 and 154, displayed more conservation than expected based on local structural
environment. Molecular dynamics simulations showed these conserved regions of ovine PrP displayed genotypic differences in
conformational repertoire and amino acid side-chain interactions. Significantly, Leu141Arg154 PrP adopted an extended beta
sheet arrangement in the N-terminal palindromic region more frequently than the Phe141Arg154 and Leu141His154 variants.
We supported these computational observations experimentally using circular dichroism spectroscopy and immunobiochemical
studies on ovine recombinant PrP. Collectively, our observations show amino acid residues 141 and 154 influence secondary structure
and conformational change in ovine PrP that may correlate with different forms of scrapie.
1. Introduction
Prion diseases, or transmissible spongiform encephalop-
athies (TSEs), are fatal neurodegenerative disorders that
affect humans and other vertebrate species. These conditions
include scrapie in sheep, bovine spongiform encephalopathy
(BSE) in cattle, and Creutzfeldt-Jakob disease (CJD) of
humans. Collectively, these diseases can manifest as inher-
ited, infectious, or sporadic conditions [1]. A central event
of prion pathogenesis is the structural conversion of the 𝛼-
helix-rich host protein PrPC into an abnormal isomer PrPSc,
char-acterised by an increase in 𝛽-sheet structure [2, 3]. PrPC
is a copper binding [4, 5] cell-surface glycoprotein that com-
prises a relatively unstructured N-terminal domain and a
predominantly globular C-terminal region containing three
𝛼-helices interdispersed by a short antiparallel 𝛽-sheet region
[6–11].The globular domain demonstrates a close association
between helix-1, the C-terminal region of helix-2, and the N-
terminal region of helix-3. This central core is bound by an
intramolecular disulphide bond between amino acid residues
in helix-2 and helix-3. Characterisation of the protein folding
events that occur during the conformational change in PrP
during prion disease is crucial to an understanding of the
formation of PrPSc and its subsequent oligomerisation.
Scrapie disease of sheep is the prototypic prion dis-
ease. Four major polymorphisms in the ovine prion protein,
located at amino acid residues 136, 141, 154, and 171, are asso-
ciated, in some cases relatively [12, 13], with susceptibility
to two classifications of scrapie disease [13–16]. Animals
that express V136L141R154Q171 (VLRQ) or A136L141R154Q171
(ALRQ) ovine PrP are susceptible to classical scrapie, a trans-
missible form of ovine prion disease [17]. In contrast, atypical
scrapie disease of sheep has been reported in classical scrapie-
resistant PrP genotypes including A136L141R154R171 (ALRR),
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A136F141R154Q171 (AFRQ), and A136L141H154Q171 (ALHQ)
[18]. Atypical scrapie disease usually occurs in old sheep and
is not considered to be naturally transmissible. Epidemiolog-
ical studies suggest that the ovine PrP allelic variants AFRQ
and ALHQ are associated with the highest susceptibility
to atypical scrapie disease [13] and that this condition is a
spontaneous disorder of PrP folding and metabolism [18, 19],
although natural transmission by oral exposure cannot yet be
excluded [20].
Critical amino acid residues will determine the range or
stability of structural changes within the ovine prion protein,
or its functional interaction with potential cofactors, during
conversion of PrPC to PrPSc. Computational techniques can
be used to predict functional or critical structural amino acid
residueswithin a specific protein [21–23].The conservation of
individual amino acids with a polypeptide sequence has been
shown to be strongly dependent on the environment inwhich
the residues occur in the protein structure [24, 25].Therefore,
the application of conservation of sequence analysis is able to
distinguish between evolutionary restraints arising from the
need to preserve protein function and those that arise from
the preservation of the protein’s structural environment. We
have previously performed molecular dynamics simulations
(mds) of the ovine PrP allelic variants VLRQ, ALRQ, and
ALRR in order to determine how genotypic variation at
amino and residues 136 and 171 influences conformational
variation in ovine prion protein variants associated with
susceptibility to classical scrapie [26]. Here we have used a
combined computational and experimental approach using
ALRQ, AFRQ, and ALHQ ovine PrP in order to determine
how genotypic variation at amino acid residues 141 and 154
influences conformational variation in conserved regions of
ovine prion protein variants associated with susceptibility to
atypical scrapie.
Computationally, we have identified regions of the ovine
PrP protein, some in close proximity to amino acid residues
141 and 154, which display a higher degree of conserva-
tion than would be expected on the basis of the local struc-
tural environment. These conserved regions of ovine PrP,
which likely represent critical structural amino acid residues,
showed genotypic differences in the range of structural con-
formations and amino acid side-chain interactions that could
be adopted when analysed by mds. Significantly, an increase
in 𝛽-sheet content involving amino acid residues 112–121
occurred most frequently in the ALRQ variant and least
frequently in ALHQ.We have supported these computational
observations with experimental studies. The propensity for
sarkosyl- or copper-induced conformational change in ovine
recombinant PrP, measured by circular dichroism (CD)
spectroscopy and capture-detector ELISA, respectively, was
in the order ALRQ ≥AFRQ >ALHQ. Furthermore, amongst
the three ovine PrP genotypes analysed, the ALRQ variant
showed the highest propensity for aggregation. Collectively,
these observations show that variants of ovine PrP display dif-
ferences in secondary structure and conformational change.
The data suggest a structural correlation for genotypic vari-
ants of ovine PrP and their association with different forms
of scrapie.
2. Materials and Methods
2.1. Sequence Conservation Analysis. The Crescendo algo-
rithm was used to identify amino acid substitutions that are
likely to be involved in protein function or protein inter-
actions [27].This algorithm compares the observed sequence
conservation for each amino acid position in the homolo-
gous sequences of a protein with the conservation pattern
predicted on the basis of local environment substitution
tables. Tables of the log-odds probability values of finding
a given amino acid substitution, in a given structural envi-
ronment, have previously been calculated for a variety of
structural environments [24, 25]. Commonly used definitions
of the structural environments include the accessibility of
the side-chain of the amino acid to solvent; the conforma-
tion of the backbone of the amino acid (helix, strand, and
coil); and whether the amino acid forms hydrogen bonds
with other amino acids or ligands. These probability values
represent the average substitution frequency of exchange of
two amino acids in a given structural environment seen in
the HOMSTRAD database of structurally derived sequence
alignments [28]. Using the structure of the accepted wild
type form of ovine PrP, the ALRQ allelic variant, an expected
sequence substitution pattern for each amino acid posi-
tion, given its structural environment, can be derived from
the tables of the log-odds probability values. Accordingly,
sequences homologous to ALRQ ovine PrP were identified
by a BLASTp search [29] against the NCBI database, using
the BLOSUM62 substitutionmatrix and an E-value threshold
of 10−6. Mutant or incomplete PrP sequences were removed
from the analysis. Alignment of homologous PrP amino
acid sequences via the Crescendo algorithm (http://www
.bioinf.manchester.ac.uk/crescendo) allowed the observed
sequence substitution pattern of amino acids at every position
in the polypeptide chain to be determined. The Kullback-
Leibler conservation score, which is a measure of statistical
similarity between the observed and expected sequence sub-
stitution distributions, was subsequently calculated [30].This
sequence conservation score identifies the residue positions
that have a higher degree of observed sequence conservation
than would be expected on the basis of the local struc-
tural environment. These additional restraints on allowed
amino acid substitutions are either due to unusual structural
requirements of the particular protein fold or to particular
functions mediated by interactions with other molecules.
Crescendo conservation scores associated with every amino
acid residue was assigned to the three-dimensional coordi-
nate of the atommost likely to be responsible for conservation
of that particular amino acid. A three-dimensional Gaussian
mask was placed at the position of the chosen coordinate
and residue scores summed with scores from other residues
if they were close in three dimensions (within the expanse
of the mask). These summed mask scores were contoured
and mapped onto the surface of the crystal structure of the
ALRQ ovine PrP (PDB code 1TPX). The averaging, mask-
ing, and contouring were performed using the Kin3Cont
component of the Kinemage suite of software (available at
http://kinemage.biochem.duke.edu/).
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2.2. Comparative Modelling. Models of the C-terminal
domain (amino acid residues 110–228) of the ALRQ, AFRQ,
andALHQvariants of ovine PrPwere built using the program
MODELLER [31] using default parameters based upon the X-
ray structure of ovine PrP (PDB code 1TPX) [32]. The region
that comprised amino acid residues 112–121 was built as an
𝛼-helix of 3 turns based on secondary structure predictions
using the prediction program Jpred [33].
2.3.MolecularDynamics Simulations. Themolecular dynam-
ics simulations (mds) were carried out with the program
Gromacs [34] using the OPLS-AA/L all-atom force field. A
model of each allelic variant of ovine PrP was placed in an
80 × 80 × 80 A˚ box containing approximately 5500 water
molecules and energyminimised for 1000 steps to remove any
unfavourable contacts. Simulations were performed for each
allele at 300K for 15 ns at neutral pH (pH 7, above the pKa
of histidine). Accordingly, glutamate and aspartate residues
were negatively charged; lysine and arginine were positively
charged and histidine residues were neutral. The simulations
(𝑛 = 7 for each PrP variant) were carried out using 1 fs
step size and the coordinates saved every 100 ps. Long-range
electrostatic interactions were calculated using Particle Mesh
Ewald.
2.4. Cloning, Expression, and Purification of Ovine Recom-
binant PrP. Expression constructs for mature length AFRQ
and ALHQ ovine PrP (amino acid residues 25–232) were
generated by site-directed mutagenesis of wild type ALRQ
ovine PrP DNA (with methionine at residue 112) in a pET23b
backbone [35]. Mutations were verified by DNA sequenc-
ing. Recombinant PrP was purified from BL21(DE3) pLysS
Escherichia coli expressing ovine PrP in a method adapted
fromHornemann et al. [7] and described in detail previously
[36]. Oxidised and refolded recombinant PrP was stored at
−80∘C.
2.5. Anti-PrP Monoclonal Antibodies. The anti-PrP mono-
clonal antibodies FH11 [37] andV47 [38] have been described
in detail previously. Monoclonal antibodies FH11 and V47
react with amino acid residues 54–58 and 217–232 of ovine
PrP, respectively.
2.6. Metal-Ion Treatment of Ovine Recombinant PrP. Recom-
binant PrP (20𝜇M) was dialysed into water at 4∘C for 1 day
with mild stirring before incubation with copper or man-
ganese sulphate at 0.2mM or 2.0mM at 37∘C for 20 hours.
Samples were maintained at 4∘C for a further 5 days prior to
use in ELISA.
2.7. Sarkosyl Treatment of Ovine Recombinant PrP. 20𝜇M
recombinant PrP in 50mM sodium acetate (pH 5.0) was
incubated with 0.005% or 0.008% (final concentration v/v)
sarkosyl (prepared in MilliQ water) at 37∘C for 1 hour.
Reaction tubes were incubated at 4∘C for 5 minutes. The
samples were centrifuged at 13,000×g for 3–5 seconds and the
supernatant analysed by CD spectroscopy.
2.8. Circular Dichroism Spectroscopy. Samples of recombi-
nant PrP at concentrations of 25 𝜇M prepared in 50mM
sodium acetate were used for CD spectroscopic analysis. All
samples were centrifuged at 13,000×g at 4∘C for 30 minutes
prior to analysis. CD spectra were recorded in a 0.5mm
path-length quartz cuvette at 20∘C, under constant nitrogen
flushing using a JASCO 810 spectropolarimeter. At least 10
spectra were accumulated and the values were expressed
as molar ellipticity (𝜃). Secondary structure content was
determined from deconvoluted CD spectroscopic data using
the CDNN programme [39, 40].
2.9. ELISA. Direct ELISA: recombinant PrP protein samples
at the desired concentration were coated onto 96-well flat-
bottomed plates and incubated overnight at 4∘C. Excess
antigen was removed and the wells blocked with PBS con-
taining 5% non-fat milk for 1 hour at 20∘C. Plates were
washed three times with PBS containing 0.1% Tween 80
(PBS-T). A 50𝜇L volume of purified anti-PrP monoclonal
antibody at 3 𝜇g/mL was added to the wells and the plates
were incubated for 1 hour at 20∘C, followed by three washes
with PBS-T. Subsequently, 50𝜇L of anti-mouse IgG-biotin
conjugate (Sigma) was added to the wells at a dilution of
1 : 3000 and plates were incubated for 1 hour at 20∘C, followed
by three washes with PBS-T. The ELISA was completed
as described below. Aggregation-specific ELISA: anti-PrP
monoclonal antibody V47 was coated onto 96-well flat-
bottomed plates at 1 𝜇g/well and incubated overnight at 4∘C.
Excess antibodywas removed and thewells were blockedwith
PBS containing 1%fish gelatin for 2 hours at 20∘C, followed by
three washes with PBS-T. Recombinant PrP protein samples
at the desired concentration were added to the wells and the
plates were incubated for 1 hour at 20∘C, followed by three
washes with PBS-T. Biotinylated monoclonal antibody V47
at 1 𝜇g/mL was added to the wells for 1 hour at 20∘C, followed
by three washes with PBS-T. The ELISA was completed as
described below. Colour development in both the direct and
the aggregation-specific ELISA was achieved by the addition
of 50𝜇L of avidin-alkaline phosphatase conjugate (Sigma) at
1 : 2000 dilution and plates were incubated for 1 hour at 20∘C.
The plates were then washed three times in PBS-T and once
with ELISA buffer (0.05M glycine, 0.03M NaOH, 0.25mM
MgCl
2
, and 0.25mM ZnCl
2
) before addition of 50 𝜇L of
the substrate p-nitrophenyl phosphate (Sigma) at 0.5mg/
mL in ELISA buffer for 30–60 minutes at 20∘C. Absorb-
ance was measured at 415 nm on a Bio-Rad 680 microplate
reader.
2.10. Statistical Analysis. Statistical analyses of the data,
where relevant, was performed using one-way ANOVA with
TukeyHSD (honestly significant difference) for post hoc anal-
ysis or the two-tailed Student’s 𝑡-test (unpaired samples)
for analyses between genotypes using the Prism 4 software
package (GraphPad).
2.11. Nomenclature. Amino acid residue numbers refer to the
ovine PrP sequence unless stated otherwise.
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Table 1: Sequence conservation scores for amino acid residues in
ovine PrP predicted by the Crescendo algorithm. Ovine PrP amino
acid residues with conservation scores >1 are listed. The conser-
vation score quantifies the degree of sequence conservation at an
alignment position compared to the average sequence conservation.
A score of >1 means the sequence conservation is more conserved
than that expected based upon its structure.
Conservation
score Amino acid residue Structural position
2.28 Met157 Helix-1
2.13 Gln163 𝛽-strand-2
2.08 Met 132 𝛽-strand-1
1.80 Thr194 C-terminus of helix-2
1.73 Thr195 C-terminus of helix-2
1.70 Thr191 C-terminus of helix-2
1.70 Thr219 Helix-3
1.67 Asn176 Helix-2
1.47 His143 𝛽-strand-1-helix-1 loop
1.40 Gln220 Helix-3
1.38 His190 C-terminus of helix-2
1.38 His114 N-terminal domain
1.37 Gln215 Helix-3
1.35 Gln175 Helix-2
1.35 Thr204 Helix-3
1.21 Asn156 Helix-1
1.01 Ala136 𝛽-strand-1
3. Results
3.1. Sequence Conservation and Molecular Dynamics Simula-
tions. The NMR structures of PrP from a variety of different
mammalian species have now been described, as well as
crystal structures of the globular domain of human and ovine
PrP [6, 7, 9, 11, 32, 41–44]. In all of the species investigated so
far, PrP consists of a flexible N-terminal region comprising
≈100 amino acids followed by a globular C-terminal region
of ≈100 amino acids. The overall fold of the crystallised part
of the C-terminal domain of ovine PrP is predominantly
globular and contains 3 helices that comprised helix-1 (amino
acid residues 146–158); helix-2 (amino acid residues 174–
196); and helix-3 (amino acid residues 203–228) [32]. Helix-
1 was flanked by 𝛽-strand-1 (amino acid residues 129–134)
and 𝛽-strand-2 (amino acid residues 163–167) [32]. A stable
disulphide bond was predicted between Cys182 and Cys217,
which connected helix-2 and helix-3, while Asn184 and
Asn200were predicted to beN-linked glycosylation sites [32].
In order to predict functional or critical structural amino
acid residues that may contribute to the conformational
change within PrP, we subjected the protein to computational
analysis. We first analysed homologous PrP sequences from
different species (a total of 284 sequences from 131 species)
by the Crescendo method [27] to identify the degree of con-
servation of individual amino acids in the prion protein.
Sequences homologous to ALRQ ovine PrP were identified
by a BLASTp search [29] against the NCBI database.The data
in Table 1 list amino acids within the PrP molecule that have
Helix-3
Helix-2
Helix-1
Residue 154
Residue 141
Residue 136
Figure 1: Location of clusters of high sequence conservation within
the ovine PrP molecule. Sequence conservation scores for all the
amino acids in PrP were mapped on the crystal structure of ALRQ
ovine PrP and neighbouring residue scores contoured. The blue
colouration highlights those areas with the greatest degree of
sequence conservation.
a conservation score of >1, which is indicative of those
residues more conserved than expected based upon its
structure. This analysis showed that there are several regions
within ovine PrP where the amino acid sequence was more
conserved than expected. These regions were located around
(i) amino acid Met157 in helix-1; (ii) amino acid His143;
(iii) the loop between helix-2 and helix-3, which comprised
amino acid residues 198–202; (iv) amino acid 136, with two
conserved lobes, one centered uponMet132 in 𝛽-strand-1 and
the other on Gln163 in 𝛽-strand-2. The locations of clusters
of high sequence conservation within the ovine PrPmolecule
were contoured andmapped, where possible, onto the surface
of the ALRQ variant and are shown in Figure 1.
We subsequently performed mds with models of ALRQ,
AFRQ, and ALHQ ovine PrP in order to investigate how the
polymorphisms at amino acid residues 141 and 154 affected
the conformational variation of the conserved regions of
the ovine prion protein. The region around the conserved
amino acid Met157 of helix-1 was heavily influenced by
genotypic variation at amino acid residues 141 and 154 of
ovine PrP as shown in Figure 2(a). The charged amino acid
residues within helix-1 formed many conserved side-chain
interactions that stabilised its helical structure and orienta-
tion. These interactions include Glu149 with Asn146; Asp147
with Arg151 and Glu155; His143 with Arg231. In the ALRQ
variant, there were additional interactions that involved the
solvent exposed Arg154 with the side-chain of Asp150 and
the backbone of Leu142. However, in the AFRQ genotype,
the latter interactions were rarely seen.The Phe141 formed an
extended aromatic-stacking interaction with Phe144, Tyr153,
andTyr160. Similarly, inALHQovine PrP,His154 also formed
extended aromatic-stacking interactions with Phe144 and
Tyr153. These different interactions in the vicinity of helix-1
subsequently have an effect on the structure and secondary
structure content of other regions of the C-terminal domain
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Leu141
Asp150
Arg154
AFRQ ALHQ
His154
Leu141Phe141
Arg154
(a)
Helix-1
Helix-3
Helix-2
(b)
Figure 2: Ribbon diagrams that demonstrate structural features of ovine PrP. (a) Side-chain interactions in the vicinity of ovine PrP helix-1.
Amino acid residue positions 141 and 154 are shown inmagenta. Amino acid residueArg154 that is present in theALRQallelic variant provides
an extra interaction with Asp150. In contrast, the Phe141 in AFRQ and His154 in ALHQ interact with the aromatic stack that comprises
amino acid residues Phe144, Tyr153, and Tyr160. (b) N-terminal 𝛽-sheet region of ALRQ.The structure of ALRQ forms an extended 𝛽-sheet
comprising amino acid residues 112–121, 𝛽-strands 1 and 2 aftermds.
of ovine PrP, in particular helix-2. Important interactions that
normally maintain the structure of the last turn of helix-2
involve the side-chains of Gln189,Thr193,Thr194,Thr195, and
Lys197, which are conserved amino acids, highlighted by the
Crescendo analysis.
The loop between helix-2 and helix-3 was influenced by
the helix-2 secondary structure. Helix-2 was unwound at its
C-terminus by up to two turns in theALRQallelic variant and
this unwinding occurred to a lesser extent and less frequently
in ALHQ and AFRQ ovine PrP. A key interaction seen
in all three allelic variants of ovine PrP occurred between
the highly conserved amino acid His190 in helix-2 and the
backbone of Arg159 in the loop between helix-1 and𝛽-strand-
2, which limits the unwinding of helix-2. This interaction
would be lost at low pH allowing for more unwinding of
helix-2 and a greater conformational change, especially in
ALRQ ovine PrP, as we have previously suggested [45]. This
extensive unwinding of helix-2 at low pHhas also been shown
for Syrian hamster PrP (amino acid residues 90–231), which
also possessed anArg residue at the equivalent codon to ovine
amino acid residue 154 [46].
Amino acid residues 116–123 of ovine PrP comprise a
palindromic sequence (AGAAAAGA) that is present in a part
of ovine PrP that has been considered as disordered [32].
Significantly, ourmds analysis reported here showed that the
region around the palindromic sequence and the conserved
region around amino acid residue 136 of ovine PrPunderwent
structural changes that were influenced by polymorphisms
at amino acids 141 and 154. In the ALRQ variant, the helical
region comprising amino acid residues 112–121, present at the
start of themds, unwound completely and resulted in the for-
mation of additional 𝛽-strands, forming an extended 𝛽-sheet
with 𝛽-strands 1 and 2 as shown in Figure 2(b). This helical
unwinding and increase in 𝛽-sheet content occurred most
frequently in the ALRQ variant (28%) and least frequently in
ALHQ ovine PrP (18%). A network of interactions that sta-
bilised the formation of these additional 𝛽-strands occurred
between several of the amino acid residues highlighted by the
Crescendo analysis including His114, Ala136, Gln163, Gln215,
Thr219, and Gln220. While the N-terminal region of PrP
has been regarded as a disordered protein domain [47, 48],
it paradoxically influences structure in the remainder of
the protein [49]. Here we found that the formation of the
extended 𝛽-sheet structure in the N-terminal region of ovine
PrP correlated with the structural changes in the C-terminal
domain of the protein. Specifically, the last two turns of helix-
3 (from Gln220) were found to unwind and move towards
helix-2. These C-terminal structural changes allowed the
formation of an extensive network of interactions between
amino acid residues Tyr221, Arg223, and Glu224 of helix-3
and the backbone of amino acid residues 160, 170, 172, and
173 within the 𝛽-strand 2-helix-1 loop.
3.2. Generation of Ovine Recombinant PrP. Collectively, our
computational analysis has shown that genotypic variation
at amino acid residues 141 and 154 within ovine PrP has the
potential to induce local and long-range effects upon con-
served regions of amino acid sequence in the protein that
are likely to regulate its structure and therefore its con-
formational change. In order to attempt to validate this com-
putational analysis we performed structural studies with
ALRQ, AFRQ, and ALHQ ovine recombinant PrP. These
polymorphic variants of ovine PrP were produced from a
pET23b-mediated prokaryotic expression system [35]. Con-
sistent with the expected secondary structure all three PrP
isoforms produced CD spectra indicative of an 𝛼-helical
enriched protein at pH 5.0 (data not shown).
3.3. Sarkosyl Induces Conformational Changes in Ovine
Recombinant PrP. Anionic detergents such as sarkosyl have
been reported to induce 𝛽-sheet conformation in PrP leading
to amorphous and fibrillar aggregation [50, 51]. The impact
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Figure 3: CD spectra of sarkosyl-treated ovine recombinant PrP. Conformational changes of (a) ALRQ; (b) AFRQ; or (c) ALHQ ovine
recombinant PrP following treatment with water (continuous line); 0.005% sarkosyl (large dashed line); or 0.008% sarkosyl (small dashed
line). Data shown are representative CD spectra for different batches of ovine recombinant PrP ALRQ (𝑛 = 5); AFRQ (𝑛 = 1); and ALHQ
(𝑛 = 3).
of polymorphisms in ovine PrP on sarkosyl-induced con-
formational changes was investigated by CD spectroscopy.
Following exposure to sarkosyl the CD spectroscopic profiles
of all three ovine PrP variants showed changes indicative of
an increase in the proportion of 𝛽-sheet secondary structure
as shown in Figure 3. Secondary structure analysis of the
profiles, using the CDNN algorithm, indicated that the 𝛽-
sheet content of ALRQ PrP increased from 21.7 ± 1.0%
in the absence of sarkosyl to 34.8 ± 4.2% after exposure
to 0.008% sarkosyl; AFRQ PrP showed an increase from
22.5% to 35.9%; and ALHQ PrP showed an increase from
23.3 ± 0.7% to 28.2 ± 2.4%. The relative percentage increase
of 𝛽-sheet content following exposure to 0.008% sarkosyl
was approximately 60% in ALRQ and AFRQ but only 21%
in ALHQ ovine PrP. To further quantify these changes we
measured the molar ellipticity of ovine PrP at the maxima
and minima wavelengths characteristic of 𝛼-helical proteins
(193 nm, 208 nm, and 222 nm) and those with well-defined
antiparallel 𝛽-pleated sheets (195 nm and 218 nm). After
exposure to sarkosyl, ALRQ ovine PrP demonstrated changes
in molar ellipticity values that were consistent with a loss
of 𝛼-helical secondary structure and an increase in 𝛽-sheet
structure as shown by the data in Table 2.The same trend was
shown by bothAFRQ (data not shown) andALHQovine PrP.
The absolute changes in molar ellipticity values for sarkosyl-
treated ALRQ ovine PrP were significantly greater in both
extent andmagnitude than the similarly treated ALHQ allelic
variant (𝑃 < 0.05 at the stated values).
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Table 2: Quantitative changes in molar ellipticity values of sarkosyl-treated ovine recombinant PrP. Batches of ovine recombinant PrP ALRQ
(𝑛 = 5) and ALHQ (𝑛 = 3) were analysed by CD spectroscopy following treatment with sarkosyl as described in Section 2. Results are mean ±
standard deviation molar ellipticity values at wavelengths characteristic for 𝛼-helical (193 nm, 208 nm, and 222 nm) and 𝛽-sheet (195 nm
and 218 nm) proteins. Figures in brackets show percentage change in molar ellipticity values between sarkosyl- and water-treated samples.
Statistical analyses of the data for individual PrP genotypes were performed using one-way ANOVA with Tukey HSD (honestly significant
difference) for post hoc analysis or the two-tailed Student’s 𝑡-test (unpaired samples) for analyses between genotypes using the Prism 4 software
package (GraphPad).
Ovine PrP Sarkosyl Molar ellipticity (deg⋅cm
2
⋅dmol−1) × 10−3
193 nm 208 nm 222 nm 195 nm 218 nm
ALRQ
None 14032 ± 2978 −9944 ± 642 −8879 ± 694 11779 ± 2205 −9624 ± 853
0.005% 10530 ± 2176(25%)
−6489 ± 1077∗
(35%)
−7195 ± 486∗
(19%)
9102 ± 1886
(23%)
−7562 ± 716∗
(21%)
0.008% 7708 ± 2012
∗
(45%)
−3576 ± 1311∗
(64%)
−4706 ± 1077∗
(47%)
6369 ± 1106∗
(46%)
−4819 ± 1354∗
(50%)
ALHQ
None 12690 ± 1952 −9988 ± 1713 −8703 ± 551 10993 ± 3150 −9643 ± 695
0.005% 10454 ± 1594(18%)
−7506 ± 1290
(25%)
−8274 ± 662†
(5%)
10131 ± 1882
(8%)
−8969 ± 448†
(7%)
0.008% 10833 ± 3237(15%)
−5315 ± 1962∗
(47%)
−7786 ± 831†
(11%)
9595 ± 1704†
(13%)
−7945 ± 602∗†
(18%)
∗
𝑃 < 0.05 for sarkosyl treatment in comparison with no sarkosyl treatment.
†
𝑃 < 0.05 for ALRQ versus ALHQ.
3.4. ELISA Measurement of Secondary Structural Changes in
Cu2+ Treated PrP. The conformational changes in ovine PrP
that result in a decrease in 𝛼-helical content and an increase
in 𝛽-sheet structure may reflect a change in epitope exposure
within the prion protein. To assess this, ovine PrP secondary
structural changes induced by Cu2+ treatment were analysed
by ELISA using anti-PrP monoclonal antibodies as shown in
Figure 4. Treatment with either 0.2 or 2mM Cu2+, reduced
the reactivity of ALRQ PrP with the N-terminal specific anti-
PrP monoclonal antibody FH11 by >50% (Figure 4(a)) but
did not alter the reactivity of ALHQ (Figure 4(b)). Reactivity
to the C-terminal-specific monoclonal antibody V47 was
reduced to a greater extent for ALRQ (Figure 4(c)) than
for ALHQ PrP (Figure 4(d)). The response of Cu2+-treated
AFRQ PrP to FH11 was intermediate to that seen for ALRQ
and ALHQ, whilst that to V47 was similar to that of ALRQ
(data not shown).These conformational changes in PrP were
specific for Cu2+ as treatment with Mn2+ produced much
more limited changes in conformation (Figures 4(e)–4(h)).
3.5. Genotypic Differences in Ovine PrP Aggregation. We
investigated the potential of different genotypes of ovine
PrP to aggregate through the use of an aggregation-specific
ELISA. This immunoassay was designed on the rationale
that PrP aggregates might be expected to display multiple
copies of an epitope recognised by an anti-PrP monoclonal
antibody while monomeric PrP protein will have only one
copy of the epitope exposed [52]. Consequently, we used the
same anti-PrPmonoclonal antibody to detect aggregated PrP
molecules, unlike a conventional capture-detector ELISA that
utilises two different monoclonal antibodies.
The data in Figure 5(a) show the reactivity of different
allelic variants of ovine PrP in the aggregation-specific ELISA
that utilised anti-PrP monoclonal antibody V47, whereby
an increase in reactivity is indicative of PrP aggregation. The
order of reactivity in this ELISA for ovine PrP that had been
aged for 12 months was ALRQ > AFRQ > ALHQ. When
ovine PrP was aged for 18 months and then assessed by
the aggregation-specific ELISA, the level of reactivity of the
ALRQ variant was decreased, while the level of reactivity
seen by AFRQ and ALHQ PrP was increased compared with
the equivalent genotype of PrP aged for 12 months (data
not shown). As a control, the total level of age-matched
PrP protein was assessed by direct ELISA using anti-PrP
monoclonal antibody V47. The data in Figure 5(b) show that
the different allelic variants of ovine PrP showed a similar
reactivity in the direct ELISA, which confirmed that similar
levels of PrP protein were present in each sample.
4. Discussion
A fundamental event in the pathogenesis of prion diseases,
such as scrapie of sheep, is the misfolding of PrPC and the
accumulation of PrPSc. It is important therefore to study
PrP structural changes so as to understand the molecular
mechanisms of misfolding and aggregation and how these
processes may be regulated. Here we have investigated how
genotypic variation at amino acid residues 141 and 154, which
are associatedwith susceptibility to atypical scrapie, influence
conformational variation in conserved regions of the ovine
prion protein.
We utilised the Crescendo method to identify those
amino acid residues in ovine PrP with a higher degree of
conservation than expected on the basis of the local struc-
tural environment and they were therefore considered to
be evolutionary conserved. All of the identified amino acid
residues were solvent exposed and their positions within PrP
were spread across most regions of the protein. The most
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Figure 4: ELISA reactivity of metal ion-treated ovine recombinant PrP. Ovine recombinant PrP ALRQ (a, c, e, g) or ALHQ (b, d, f, h)
was treated with water (black square) or either 0.2mM (black circle) or 2mM (black triangle) copper (a–d) or manganese (e–h) at 37∘C as
described in Section 2. Serial 2-fold dilutions of recombinant PrP were analysed by direct ELISA for reactivity with anti-PrP monoclonal
antibody FH11 (a, b, e, f) or V47 (c, d, g, h). The data shown are the means of triplicate wells ± SD.
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Figure 5:Aggregation-specific ELISA reactivity of ovine recombinant PrP.Ovine recombinant PrPALRQ (black circle), AFRQ (black square),
and ALHQ (black triangle) aged 12 months was analysed by (a) aggregation-specific ELISA and (b) direct ELISA using anti-PrP monoclonal
antibody V47 as described in Section 2. Serial 2-fold dilutions of recombinant PrP were analysed as shown.The data shown are the means of
triplicate wells ± SD.
conserved region, and also that with the largest exposed
surface, was found to be the loop between helix-2 and helix-
3, which comprised amino acid residues 198–202. We have
previously identified this as a region of genotypic structural
variation with regard to the ALRR, ALRQ, and VLRQ allelic
forms of ovine PrP [26]. This region has been identified
as one of potential structural importance in the conversion
of PrPC to PrPSc by NMR studies that show perturbation
of the helix-2-helix-3 loop in denaturant-induced folding
intermediates [53]. Furthermore, mutations in this region are
associated with distinct types of human prion disease. For
example, the mutation F198S in human PrP is associated with
a familial form of Gerstmann-Stra¨ussler-Scheinker (GSS)
disease [54], whilst the E200K mutation is associated with
familial CJD [55]. A second region displayed two conserved
lobes, one centered upon Gln163 in 𝛽-strand-2 and the
other on Met132 in 𝛽-strand-1 that flanks amino acid residue
Ala136. The mutation of Ala136Val in ovine ALRQ PrP
gives rise to the VLRQ allelic variant that is associated
with high susceptibility to classical scrapie disease of sheep
[17]. In addition, this conservation cluster lies within that
segment of PrP that displays a high structural plasticity [56–
59]. Two other regions of PrP, one centered on amino acid
residue Met157 in helix-1 and nearby amino acid residue
His143, showed significant sequence conservation. These are
close to the sites of polymorphisms associated with atypical
scrapie-susceptible genotypes, namely, amino acid residues
141 and 154. Collectively, PrP sequence conservation analysis
has shown that, in addition to the well-established scrapie-
susceptibility associations of amino acid residues 136 and 171,
Met132 at the start of 𝛽-strand-1; His143; Met157 in helix-
1; and the helix-2-helix-3 loop region may be required for
the structural stability of the prion protein or are involved
in hitherto unidentified molecular interactions, for example,
oligomeric formation.
In common with other species forms of PrP, ovine PrP
contains a predominantly globular C-terminal domain and
a less structured N-terminal region [6, 8–11, 32, 41–44]. We
have previously shown thatmds can provide good agreement
between modelled structures of ovine PrP and those derived
by experimental studies [26]. Here we have used mds to
model amino acid residues 110–228 of ovine PrP in order
to determine the effect of polymorphisms in the 𝛽-strand 2-
helix-1 loop on the conserved regions of this protein.Ourmds
analysis showed that while the general features of the PrP fold
were retained, as seen for previous experimentally derived
structures of ovine PrP [32, 44], significant differences were
evident in the formation and interaction of secondary struc-
tural elements within the different prion protein genotypes.
Significantly, we have found that the region comprising
amino acid residues 112–124, which includes the palindromic
sequence comprising amino acids AGAAAAGA, was able to
form additional 𝛽-strands that resulted in the formation of
an extended antiparallel𝛽-sheet arrangement in combination
with 𝛽-strands 1 and 2. This increase in 𝛽-sheet content
also showed genotype variation, occurring most frequently
in ALRQ and least frequently in ALHQ ovine PrP.The region
around the palindromic sequence PrP has been predicted
to form 𝛽-strands [60] but inherent disorder has hampered
determination of its structure. Experimental evidence for
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the formation of an extended 𝛽-sheet arrangement in this N-
terminal region has been achieved by the recent cocrystali-
sation of human PrP with an anti-PrP monoclonal antibody
[61]. While the N-terminal region of PrP has been regarded
as a disordered protein domain [47, 48], our observation
here and similar observations by others [60, 61], of the
formation of an extended 𝛽-sheet arrangement in the vicinity
of the palindromic sequence, suggests that the N-terminal
region of PrP has more structure than previously proposed.
Alternatively, this region of the N-terminal domain of PrP
may serve as a site that mediates 𝛽-sheet enrichment during
the formation of disease associated PrP. It has been shown
that peptide fragments of PrP that contain the palindromic
sequence show a high tendency to aggregate into𝛽-sheet-rich
amyloid fibrils [62] and are neurotoxic [63].
The N-terminal region of PrP may play a role in mod-
ulation of PrP aggregation since this region influences the
amount of secondary structure in the remainder of the
molecule [49]. Our mds analysis reported here has shown
that formation of the extended 𝛽-sheet structure in the
N-terminal region of ovine PrP correlated with significant
structural changes in the C-terminal region of the protein.
The conserved amino acid residue Met157 of helix-1 was
heavily influenced by genotypic variation at amino acid
residues 141 and 154 of ovine PrP. Differences in the inter-
actions in this region were subsequently found to have an
effect on the secondary structure content of other regions
of the C-terminal domain of ovine PrP, in particular helix-
2. Unwinding of helix-2 occurred to a lesser extent and less
frequently in the ALHQ and AFRQ ovine PrP compared to
that seen in the ALRQ allelic variant as shown here and in our
previousmds studies [26].The last two turns of helix-3 (from
Gln220)were found to unwind,which is seenmore frequently
in the ALRQ genotype. Once fully unwound, the end of helix-
3 was able to interact with the 𝛽-strand 2-helix-2 loop, which
adopted a similar conformation as seen in the other examples
of PrP that display an N-terminal extended 𝛽-sheet structure
[60, 61]. These C-terminal structural changes in ovine PrP
allowed the formation of an extensive network of interactions
between amino acid residues Tyr221, Arg223, and Glu224 of
helix-3 and the backbone of amino acid residues 160, 170, 172,
and 173within the𝛽-strand 2-helix-2 loop. Structural flexibil-
ity of the 𝛽-strand 2-helix-2 loop region and helix-3 has been
highlighted as crucial determinants for susceptibility to prion
disease [60, 64, 65]. Collectively, our computational analysis
has shown that genotypic variation at amino acid residues 141
and 154 within ovine PrP has the potential to induce long-
range effects upon conserved regions of amino acid sequence
in the protein that are likely to regulate its structure and
therefore affect its conformational change. We supported our
computational structural analysis of allelic variants of ovine
PrP with experimental studies using detergent- or copper-
induced conformational change in recombinant ovine PrP.
The anionic detergent sarkosyl is widely used in PrPSc
purification and enhances extraction efficiency of PrPSc
and stimulates the PrPSc-induced conversion reaction [66,
67]. Treatment of allelic variants of ovine recombinant
PrP with sarkosyl resulted in an increase in the propor-
tion of 𝛽-sheet secondary structure that was of the order
ALRQ ≥ AFRQ > ALHQ. This suggests that amino acid
residue 154 of ovine PrP, and the polymorphisms at this posi-
tion, contributes to the susceptibility of anionic detergent-
mediated conformational change. Previously, it has been
proposed that sarkosyl induces conformational change by
inserting detergent into the hydrophobic core of PrP, thereby
disrupting its conformation and facilitating hydrophobic pro-
tein-protein interactions [51]. Since ALHQhas been reported
to have a less exposed hydrophobic core than other allelic
variants of ovine PrP, such as VLRQ [68], the hydrophobic
interactions between detergent micelles and the core of
ALHQ may not be as extensive as that seen with other ovine
PrP variants.
TheN-terminal region of PrP contains high affinity bind-
ing sites for Cu2+ ions and acquires structure following cop-
per binding [69, 70].This N-terminal conformational change
may modulate the propensity of PrP aggregation since this
region influences the amount of secondary structure in the
remainder of the molecule [49]. As a consequence of bind-
ing Cu2+ ions, PrP undergoes conformational changes that
involve interactions between different regions of the protein
[5, 36, 71, 72]. For example, amino acid residues close to the
C-terminal region of 𝛼-helix-1 and the nearby loop between
𝛽-strand-1 and 𝛼-helix-1 interact with Cu2+ coordination
groups in the N-terminal region of the protein [73]. We have
previously found that the Met112Thr polymorphism in ovine
ALRQ PrP, located within a Cu2+-binding site in the N-
terminal region of the protein [53, 74, 75], affects copper-
induced structural changes within the C-terminal region of
the prion protein [35]. Here, we have shown by capture-
detector ELISA that the structural variation induced by Cu2+
within ALRQ ovine PrP was associated with conformational
changes in the N-terminal and C-terminal regions of the
protein but principally only in the C-terminal region of the
ALHQ variant. The modulation of epitope exposure in the
N-terminal region of ALRQ ovine PrP, determined by ELISA,
correlated with its enhanced tendency for formation of addi-
tional 𝛽-strands in this region of the protein compared to the
ALHQ variant, as shown in the mds analysis. The enhanced
detergent- and copper-induced structural changes displayed
by ALRQ ovine PrP corresponded with an increased capacity
of this genotype of ovine PrP to undergo age-induced mul-
timerisation as measured by the aggregation-specific ELISA.
However, while the ALRQ variant showed the greatest ten-
dency for aggregation amongst the different polymorphic
forms of ovine PrP tested here, after an extended period of
aging its reactivity was decreased below that of similar aged
AFRQ andALHQPrP.We speculate that the time-dependent
decrease in reactivity of ALRQ ovine PrP in the aggregation-
specific ELISA was a consequence of its greater propensity to
aggregate, compared to the AFRQ andALHQvariants, which
resulted in previously exposed epitopes subsequently becom-
ing obscured.This view is supported by our previous observa-
tion that denatured ALRQ ovine PrP undergoes a more rapid
rate of aggregation compared to the ALHQ variant [45].
The conformational properties of PrP are strongly pH-
dependent [76] and various in vitro studies have reported
a relationship between pH and misfolding and aggregation
BioMed Research International 11
of PrP [77]. However, the exact subcellular location and
therefore the pH of the environment where this process may
occur have not been fully defined. Here we have collectively
studied conformational variation in ovine PrP genotypes
at neutral and acidic pH. Neutral pH conditions are char-
acteristic of those at the plasma membrane where PrPSc
has been reported to form soon after prion exposure of
cells in vitro, even under conditions that prohibit endocytic
activity [78]. Acidic pH conditions are characteristic of the
intracellular endosomal compartments [79] where PrPC is
sequestered during its internalisation. Reports using in vitro
cell culture models have proposed that PrPC misfolding and
accumulation may occur during endocytosis in both late and
recycling endosomes [80–82]. Here we have found that the
same trend in genotypic conformational variation in ovine
PrP, namely, ALRQ > AFRQ > ALHQ, was seen under both
acidic and neutral pH conditions.
Transmission of classical scrapie is aided by shedding
and secretion of infectious prions into the environment from
affected animals [83]. It is reasonable to speculate that the
conformational properties displayed byALRQovine PrPmay
be a prerequisite for the formation of naturally transmissible
ovine prions, which presumably require a certain level of
stability to withstand the transmission process. This would
appear to be the case since allelic variants of ovine PrP
associated with classical scrapie have a greater efficiency
for in vitro conversion into a protease-resistant form fol-
lowing interaction with PrPSc [16, 84]. Furthermore, the
PrPSc associated with classical scrapie is more resistant to
proteolytic digest than its counterpart in atypical scrapie
[16, 84]. The distinct biochemical and biophysical signatures,
shown by different allelic variants of ovine PrP [16, 36, 84,
85], appear to be underpinned by their ability to undergo
conformational change in key conserved regions of the
protein. Using a combined computational and experimental
approach, we have shown that this conformational change
can be influenced by single amino acid mutations at amino
acid residue 141 located in the loop following 𝛽-strand-1 and
amino acid residue 154 located in 𝛼-helix-1. For example,
ALRQ ovine PrP, which is associated with classical scrapie,
showed an increased propensity to acquire increased 𝛽-sheet
content and to aggregate compared to ALHQ PrP, which
is associated with atypical scrapie. These data suggest a
structural correlation for genotypic variants of ovine PrP and
their association with different forms of scrapie.
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